IDEXX Laboratories, Inc. – LSE:0J8P.L
IDEXX Laboratories stock price today
IDEXX Laboratories stock price monthly change
IDEXX Laboratories stock price quarterly change
IDEXX Laboratories stock price yearly change
IDEXX Laboratories key metrics
Market Cap | 33.56B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 10.43 |
Revenue | 3.72B |
EBITDA | 1.15B |
Income | 866.56M |
Revenue Q/Q | 7.09% |
Revenue Y/Y | 8.56% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 30.87% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIDEXX Laboratories stock price history
IDEXX Laboratories stock forecast
IDEXX Laboratories financial statements
| Jun 2023 | 943.63M | 224.23M | 23.76% |
|---|---|---|---|
| Sep 2023 | 915.52M | 212.23M | 23.18% |
| Dec 2023 | 901.60M | 194.52M | 21.58% |
| Mar 2024 | 964.09M | 235.57M | 24.44% |
| Sep 2025 | 1.08B | 266.78M | 24.6% |
|---|---|---|---|
| Dec 2025 | 1.06B | 250.82M | 23.51% |
| Mar 2026 | 1.17B | 302.15M | 25.7% |
| Mar 2026 | 1.17B | 308.96M | 26.32% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2870806000 | 1.77B | 61.9% |
|---|---|---|---|
| Sep 2023 | 3086404000 | 1.78B | 57.96% |
| Dec 2023 | 3259925000 | 1.77B | 54.46% |
| Mar 2024 | 3353515000 | 1.78B | 53.22% |
| Jun 2023 | 200.31M | -27.47M | -151.03M |
|---|---|---|---|
| Sep 2023 | 272.43M | -27.83M | -43.03M |
| Dec 2023 | 249.85M | -30.43M | -101.84M |
| Mar 2024 | 198.58M | -106.94M | -144.07M |
IDEXX Laboratories alternative data
| Aug 2023 | 10,780 |
|---|---|
| Sep 2023 | 11,000 |
| Oct 2023 | 11,000 |
| Nov 2023 | 11,000 |
| Dec 2023 | 11,000 |
| Jan 2024 | 11,000 |
| Feb 2024 | 11,000 |
| Mar 2024 | 11,000 |
| Apr 2024 | 11,000 |
| May 2024 | 11,000 |
| Jun 2024 | 11,000 |
| Jul 2024 | 11,000 |
IDEXX Laboratories other data
| Insider | Compensation |
|---|---|
| Mr. Jonathan W. Ayers (1956) Senior Advisor & Director | $3,200,000 |
| Ms. Kathy V. Turner (1964) Chief Marketing Officer & Corporation Vice President | $1,950,000 |
Mr. Jonathan J. Mazelsky (1961) Pres, Chief Executive Officer & Director | $1,620,000 |
| Ms. Sharon E. Underberg (1961) Executive Vice President, Chief Financial Officer & Treasurer | $809,420 |
Mr. Michael J. Lane (1968) Executive Vice President and GM of Reference Laboratories & Information Technology | $724,020 |
Kerry Bennett Vice President of Investor Relations | |
Mr. John Hart Corporation Vice President of Worldwide Operations | |
Mr. Jeffery D. Chadbourne Senior Director of Accounting & Financial Reporting | |
Mr. Jeffrey Thomas Corporation Vice President & Chief Technology Officer | |
Mr. Ken Grady Corporation Vice President & Chief Information Officer |
-
What's the price of IDEXX Laboratories stock today?
One share of IDEXX Laboratories stock can currently be purchased for approximately $628.75.
-
When is IDEXX Laboratories's next earnings date?
Unfortunately, IDEXX Laboratories's (0J8P.L) next earnings date is currently unknown.
-
Does IDEXX Laboratories pay dividends?
No, IDEXX Laboratories does not pay dividends.
-
How much money does IDEXX Laboratories make?
IDEXX Laboratories has a market capitalization of 33.56B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.72% to 3.66B US dollars.
-
What is IDEXX Laboratories's stock symbol?
IDEXX Laboratories, Inc. is traded on the LSE under the ticker symbol "0J8P.L".
-
What is IDEXX Laboratories's primary industry?
Company operates in the Healthcare sector and Medical - Equipment & Services industry.
-
How do i buy shares of IDEXX Laboratories?
Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are IDEXX Laboratories's key executives?
IDEXX Laboratories's management team includes the following people:
- Mr. Jonathan W. Ayers Senior Advisor & Director(age: 69, pay: $3,200,000)
- Ms. Kathy V. Turner Chief Marketing Officer & Corporation Vice President(age: 61, pay: $1,950,000)
- Mr. Jonathan J. Mazelsky Pres, Chief Executive Officer & Director(age: 64, pay: $1,620,000)
- Ms. Sharon E. Underberg Executive Vice President, Chief Financial Officer & Treasurer(age: 64, pay: $809,420)
- Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology(age: 57, pay: $724,020)
- Kerry Bennett Vice President of Investor Relations
- Mr. John Hart Corporation Vice President of Worldwide Operations
- Mr. Jeffery D. Chadbourne Senior Director of Accounting & Financial Reporting
- Mr. Jeffrey Thomas Corporation Vice President & Chief Technology Officer
- Mr. Ken Grady Corporation Vice President & Chief Information Officer
-
How many employees does IDEXX Laboratories have?
As Jul 2024, IDEXX Laboratories employs 11,000 workers.
-
When IDEXX Laboratories went public?
IDEXX Laboratories, Inc. is publicly traded company for more then 7 years since IPO on 19 Jan 2018.
-
What is IDEXX Laboratories's official website?
The official website for IDEXX Laboratories is idexx.com.
-
Where are IDEXX Laboratories's headquarters?
IDEXX Laboratories is headquartered at One IDEXX Drive, Westbrook, ME.
-
How can i contact IDEXX Laboratories?
IDEXX Laboratories's mailing address is One IDEXX Drive, Westbrook, ME and company can be reached via phone at +20 75560300.
IDEXX Laboratories company profile:
IDEXX Laboratories, Inc.
idexx.comLSE
11,000
Medical - Equipment & Services
Healthcare
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Westbrook, ME 04092
:
ISIN: US45168D1046
:
